Utilizing Patient Experiences to Advance T Regulatory Cells in the Treatment of Autoimmune Diseases
- Manufacturing ex vivo polyclonal Tregs to secure authorisations of Treg cell therapies in GvHD and T1D
- Analysing clinical trial patient immune systems to generate novel cell therapies in the clinic
- Preparing novel autologous and allogenic Tregs to facilitate the effective scale up of manufacturing and treatment delivery to expand patient access